The import of antisera and other blood fractions to India is expected to steadily increase from $334.13 million in 2024 to $372.32 million by 2028. The year-on-year growth forecasts reflect a steady rise, with a consistent annual increase of around 2.9% to 2.6% over this period. These figures highlight a positive trend in the importation of these crucial medical goods, driven by growing healthcare demands and advancements in medical treatments.

Future trends to watch for include:

The influence of domestic production capabilities on import levels as India seeks to reduce dependency on imports.
Changes in global regulations and tariffs impacting trade agreements.
Technological advancements in blood fractionation impacting import needs.